5-Bromo-2-Chloro-4′-Ethoxydiphenylmethane CAS 461432-23-5 Dapagliflozin Intermediate

Short Description:

Name: 5-Bromo-2-Chloro-4′-Ethoxydiphenylmethane

Synonyms: 4-Bromo-1-Chloro-2-(4-Ethoxybenzyl)benzene 

CAS: 461432-23-5

Purity: ≥98.0% (HPLC)

Appearance: White to Pael Yellow Crystalline Powder

Intermediate of Dapagliflozin (CAS: 461432-26-8) in the treatment of type II diabetes 

Contact: Dr. Alvin Huang 

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Manufacturer Supply, High Purity, Commercial Production
Dapagliflozin (CAS: 461432-26-8) Related Intermediates:
5-Bromo-2-Chlorobenzoic Acid CAS 21739-92-4
5-Bromo-2-Chloro-4'-Ethoxydiphenylmethane CAS 461432-23-5
2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone CAS 32384-65-9

461432-23-5 - Chemical Properties:

Chemical Name 5-Bromo-2-Chloro-4'-Ethoxydiphenylmethane
Synonyms 4-Bromo-1-Chloro-2-(4-Ethoxybenzyl)benzene; 4-(5-Brom-2-Chlorbenzyl)phenyl-Ethylether; Dapagliflozin Bromo Impurity
CAS Number 461432-23-5
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C15H14BrClO
Molecular Weight 325.63
Melting Point 41.0 to 43.0℃
Density 1.371±0.06 g/cm3
COA & MSDS Available
Place of Origin  Shanghai, China
Brand Ruifu Chemical

461432-23-5 - Specifications:

Item Specifications Results
Appearance White to Pael Yellow Crystalline Powder Conforms
Purity / Analysis Method ≥98.0% (HPLC) 98.91%
Water (K.F) ≤0.50% 0.15%
Infrared Spectrum  Conforms to Structure Conforms 
1 H NMR Spectrum Conforms to Structure Conforms 
Test Standard Enterprise Standard Conforms 
Application Intermediate of Dapagliflozin (CAS: 461432-26-8), type II diabetes

Package & Storage:

Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

1

FAQ:

www.ruifuchem.com

461432-23-5 - Application:

4-Bromo-1-Chloro-2-(4-Ethoxybenzyl)benzene (CAS: 461432-23-5) is used as a intermediate in the synthesis of Dapagliflozin (CAS: 461432-26-8). Dapagliflozin is a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Dapagliflozin is a new antidiabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca, being approved by the European Medicines Agency (EMA) on November 12, 2012. On January 8, 2014, the US Food and Drug Administration (FDA) have approved it for being used in the treatment of type II diabetes. 

  • Write your message here and send it to us